



Arnold von Eckardstein, MD

Director of the Institute
Consultant for Laboratory Medicine
and Specialist for Clinical
Chemistry (equivalent to Swiss
Scientific Board FAMH)

University Hospital Zurich
Institute of Clinical Chemistry
Rämistrasse 100
8091 Zurich

Direct dial +41 44 255 22 60
Administrative office
+41 44 255 22 60
Fax +41 44 255 45 90
arnold.voneckardstein@usz.ch
www.usz.ch

Curriculum Vitae

Key skills

- Clinical Chemistry and Laboratory Medicine in general and specifically
- Organisation and management of clinical laboratories
- Risk factors and biomarkers of cardiovascular and metabolic diseases
- Diagnosis and therapeutic management of Dyslipidemias

Background

2003 chairman University Center of Laboratory Medicine and Pathology
2001 full professor of clinical chemistry (University of Zurich)
2001 director, institute of clinical chemistry (University Hospital Zurich)
2000 professor of laboratory medicine and clinical chemistry (University of Münster)
1994 habilitation (University of Münster)
1993 German Medical Board Certificate in laboratory medicine
1993 German Scientific Board Certificate (DGKL) in clinical chemistry
1989 doctorate in medicine
1986 license as a physician

Publications

Representative examples from previous 5 years:

- Velagapudi S, Yalcinkaya M, Piemontese A, Meier R, Nørrelykke SF, Perisa D, Rzepiela A, Stebler M, Stoma S, Zanoni P, Rohrer L, von Eckardstein A. (2017)
VEGF-A Regulates Cellular Localization of SR-BI as Well as Transendothelial Transport of HDL but Not LDL.
Arterioscler Thromb Vasc Biol. 2017 37(5):794-803.
- Alecu I, Othman A, Penno A, Saied EM, Arenz C, von Eckardstein A, Hornemann T (2017)
Cytotoxic 1-Deoxysphingolipids Are Metabolized by a Cytochrome P450- Dependent Pathway
J Lipid Res. 58(1):60-71.



- Mueller DM, Allenspach M, Othman A, Saely CH, Muendlein A, Vonbank A, Drexel H, von Eckardstein A. (2015)
Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control.
Atherosclerosis. 2015 Oct 24;243(2):638-644.
- Sutter I, Velagapudi S, Othman A, Riwanto M, Manz J, Rohrer L, Hornemann T, Landmesser U, von Eckardstein A (2015)
Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-apoptotic activity of HDL
Atherosclerosis ;241(2):539-546
- Reiser H, Klingenberg R, Hof D, Cooksley-Decasper , Fuchs N, Akhmedov A, Zoller S, Marques-Vidal P, Marti-Sole H, Heg D, Landmesser U, Rodondi N, Mach F, Windecker S, Vollenweider P, Matter C, Lüscher TF, von Eckardstein A, Gawinecka J (2015). Circulating FABP4 is a prognostic biomarker in patients with acute coronary syndrome but not in asymptomatic individuals. Arterioscler Thromb. Vasc Biol.;35(8):1872-9.

Complete list see:

<http://www.ncbi.nlm.nih.gov/pubmed/?term=von+Eckardstein+a+or+eckardstein+a+or+voneckardstein+a>

Memberships

- American Society of Biochemistry and Molecular Biology
- European Atherosclerosis Society (Executive Board Member since 2013, Editor-in-Chief of its journal "Atherosclerosis" since 2016)
- Foederatio Analyticorum Medicinalium Helveticorum
- German Atherosclerosis Society (President 2003 to 2005)
- German Society of Clinical Chemistry and Laboratory Medicine (Editor-in-Chief of its journal "Journal of Laboratory Medicine" 2000-2006)
- Swiss Society of Clinical Chemistry (Executive Board Member 2004-2012, President 2006-2008)
- Swiss Atherosclerosis Society (President 2013-2017)



Key areas of research

- Lipoproteins with a focus on High density lipoproteins
- Lipids and lipidomics with a focus on sphingolipids
- Risk factors and biomarkers of cardiometabolic diseases